Dabrafenib (GSK2118436)

製品コードS2807

Dabrafenib (GSK2118436)化学構造

分子量(MW):519.56

Dabrafenib (GSK2118436)は一種の突然変異型BRAFV600の特異性的な阻害剤で、無細胞試験でIC50値が0.8nMですが、BRAFV600に作用する効果はB-Raf(wt)とc-Rafに作用する効果より4倍と6倍がそれぞれ高くなります。

サイズ 価格 在庫  
JPY 25917.84 あり
JPY 12958.92 あり
JPY 18718.43 あり
JPY 24477.96 あり
JPY 38876.76 あり
JPY 57595.20 あり

カスタマーフィードバック(5)

  • A375P cells were treated with vehicle, the BRAF inhibitor GSK2118436, the MEK inhibitor GSK1120212, 10 uM HCQ, or the indicated combinations. Shown are 48-hour immunoblots directed against the indicated proteins.

    J Clin Invest 2014 24(3), 1406-17. Dabrafenib (GSK2118436) purchased from Selleck.

    Levels of pERK and tERK in the CLL cells derived from PBMC were measured by Western blot. We used vemurafenib, dabrafenib, and trametinib (0.07 uM) as indicated. One of 3 independent experiments with similar results is shown. CLL cells exposed to dabrafenib or vemurafenib had an elevated pERK/tERK ratio as compared with vehicle (P < 0.01).

    J Clin Invest 2014 124(11), 5074-84. Dabrafenib (GSK2118436) purchased from Selleck.

  • The effects of inhibitors of mutant BRAFV600 inhibitor dabrafenib on cancer cell growth were evaluated by the MTT assay. Cell growth inhibition of FRO and SW1736 cell lines induced by dabrafenib.

    Transl Res 2014 10.1016/j.trsl.2014.06.005. Dabrafenib (GSK2118436) purchased from Selleck.

    Dabrafenib alleviates acetaminophen-induced hepatotoxicity in mice. Mice were treated with 300 mg/kg acetaminophen (i.p.), with or without pretreatment with 300 mg/kg or 100 mg/kg dabrafenib (p.o.).TUNEL staining for nuclear DNA fragmentation in mouse liver cells.

    Cell Death Dis 2014 5, e1278. Dabrafenib (GSK2118436) purchased from Selleck.

  • Western blot analysis of p-Erk and total ERK in A375 melanoma cell line after treatment with different doses of Dabrafenib for 48 hours (A). p-ERK signal was normalized with total ERK signal (B), SD and means of the normalized p-ERK values were reported.

    PLoS One, 2016, 11(3):e0152104. Dabrafenib (GSK2118436) purchased from Selleck.

製品安全説明書

Raf阻害剤の選択性比較

生物活性

製品説明 Dabrafenib (GSK2118436)は一種の突然変異型BRAFV600の特異性的な阻害剤で、無細胞試験でIC50値が0.8nMですが、BRAFV600に作用する効果はB-Raf(wt)とc-Rafに作用する効果より4倍と6倍がそれぞれ高くなります。
ターゲット
B-Raf (V600E) [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
C-Raf [1]
(Cell-free assay)
0.8 nM 3.2 nM 5.0 nM
体外試験

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-RafV600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-RafV600E. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MX;LbY5ie2ViQYPzZZk> NXXwWmI6UW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGhqeyC2YXfn[YQhSi2UYX[gWlYxOEVibYX0ZY51KGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgZ4VtdHNiY3:t[ZhxemW|c3nu[{BETEN|NzDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCkaX;0bY56dGG2ZXStUWVMKHC{b4TlbY4heGixc4Doc5J6dGG2aX;uJIJ6KEGucHjhV4Nz\WWwIHHzd4F6KHerdHigTWM2OCCxZjCwMlAxODdizszN NIXB[mEzPDlyME[3Ny=>
SK-MEL-28 NEW5R4hMcW6jc3WgRZN{[Xl? MkfRNUBp NIf0NYpKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hTVKNIIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gNE4xODRizszN Mmf3NlQ6ODB4N{O=
HepG2 NX;3eoVOU2mwYYPlJGF{e2G7 Ml\KTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRiaX6gbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLJJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMESg{txO Mm\0NlQ6ODB4N{O=
COLO205 NHjoTFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9{MEWgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwO{DPxE1? M1P3XFI1QTByNkez
HepG2 M4[xTWZ2dmO2aX;uJGF{e2G7 MV:0OUBucW5? NHLoT3lFVVOR NWn1b2x2UW6qaXLpeIlwdiCxZjDBcIs2KGmwIGTHSk1j\XSjLYP0bY12dGG2ZXSgbJVu[W5iSHXwS|Ih[2WubIOgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5iU33h[FIheGixc4Doc5J6dGG2aX;uJJRz\WG2ZXSg[o9zKDR3IH3pcpMheHKrb4KgeI8hXEeILXLleIEhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhPjBibXnud{BjgSCxZInzd4V6KGKub4Sgd4Nidm6ncjDhcoFtgXOrczD3bZRpKEmFNUCgc4YhOy55IN88US=> MoLKNlQ6ODB4N{O=
HFF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK3NVAh|ryP M3\EW|czKGh? M4K0[2ROW09? M1;aU2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCqdX3hckBJTkZiY3XscJMhcGG{Yn;ybY5oKHerbHSgeJlx\SCELWLh[kB4cXSqIFnDOVAhd2ZiMzFOwG0> NGjDT2UzOzh2NECzPC=>
SK-MEL-28 M{\yXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNEDPxE1? NVrlXlA1PzJiaB?= M1Pxd2ROW09? M2DtU2lvcGmkaYTpc44hd2ZiQj3SZYYhXjZyMFWgcZV1[W62LXTybZZmdiCVSz3NSWwuOjhiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjB2MzFOwG0> NXLWbYFPOjN6NESwN|g>
A375P-F11 NV6yTmRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnSNVAh|ryP M4HBSlczKGh? NWLCNnpxTE2VTx?= Mln5TY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKEF|N{XQMWYyOSClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODdzIN88US=> M{j2SlI{QDR2MEO4
MALME-3M NHrPVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexNEDPxE1? MnfhO|IhcA>? M365e2ROW09? NFvSZnJKSzVyPUGgcm0> MV2yN|g1PDB|OB?=
UACC-62 NV7hOWlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fDeVExKM7:TR?= MV:3NkBp MXrEUXNQ M{\uZmlEPTB;MTDuUS=> MViyN|g1PDB|OB?=
C32TG M2n3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W4OFExKM7:TR?= NHzSSXk4OiCq MkXSSG1UVw>? MlPpTWM2OD1zIH7N M13T[VI{QDR2MEO4
SK-MEL-1 M3TLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvzNVAh|ryP NEXteIM4OiCq MVPEUXNQ NITYbGhKSzVyPUKgcm0> MUWyN|g1PDB|OB?=
M14 MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3xNVAh|ryP NHH4R4c4OiCq Mn74SG1UVw>? MVrJR|UxRTJibl2= M4PQOVI{QDR2MEO4
SK-MEL-28 M1voT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxNEDPxE1? MWK3NkBp MlWzSG1UVw>? M2HuT2lEPTB;MzDuUS=> M{LwSlI{QDR2MEO4
A375 NWq3WZFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1naRlExKM7:TR?= NInKWpk4OiCq M3X6cmROW09? MnvyTWM2OD12IH7N M3TQblI{QDR2MEO4
DU-4475 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXWRo5mOTBizszN NFjDeo44OiCq NFLrd|BFVVOR MWHJR|UxRTVibl2= NXrvVI15OjN6NESwN|g>
UACC-257 MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvTPHkyOCEQvF2= M4KxTVczKGh? NGLkeIVFVVOR MUHJR|UxRTZibl2= NIXMdmkzOzh2NECzPC=>
Colo 205 M1O2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPINVAh|ryP Mn[zO|IhcA>? NYW5[pV2TE2VTx?= Mme3TWM2OD15IH7N NEPST4UzOzh2NECzPC=>
SK-MEL-3 NETRRZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW2ZYp7OTBizszN NIjUe2M4OiCq M4\Lb2ROW09? NFnEXWdKSzVyPUegcm0> M4P4[VI{QDR2MEO4
SH-4 NWG4e4l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITubowyOCEQvF2= MlvwO|IhcA>? NWnUOHZ[TE2VTx?= NIPSfFdKSzVyPUigcm0> MWOyN|g1PDB|OB?=
A101D M4PRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\kPFExKM7:TR?= MmnrO|IhcA>? M{m0fWROW09? NWe0eW43UUN3ME25JI5O NF3wcnIzOzh2NECzPC=>
ES-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnMeJcyOCEQvF2= NUK0XVlMPzJiaB?= M1PTOGROW09? NEDQblZKSzVyPUWzJI5O MlvZNlM5PDRyM{i=
HT-29 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[xNEDPxE1? NIXXb5Q4OiCq MX\EUXNQ NEHYZ3NKSzVyPU[2JI5O NUfxPINKOjN6NESwN|g>
SW1417 M2HHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LTXVExKM7:TR?= NV\YcWpuPzJiaB?= MWrEUXNQ NV7zZ40zUUN3ME2xOVghdk1? NVfjXY5HOjN6NESwN|g>
SW872 NVzhUmpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYizOYxwOTBizszN NWjqPGN5PzJiaB?= MWXEUXNQ MWPJR|UxRTN5NzDuUS=> MXeyN|g1PDB|OB?=
RKO NGDPdmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrOWG0yOCEQvF2= MXm3NkBp MWjEUXNQ M1PCN2lEPTB;Mj61NlIh|ryP MmLUNlM5PDRyM{i=
A673 M3\pVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUSxNEDPxE1? M3zyN|czKGh? M17RUmROW09? MnzoTWM2OD1zMDFOwG0> Ml35NlM5PDRyM{i=
GCT MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfp[4d4OTBizszN M2rVfVczKGh? M3TaXGROW09? MmrpTWM2OD1zMDFOwG0> NVvHVY1jOjN6NESwN|g>
WM-115 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPONVAh|ryP MX23NkBp MlmySG1UVw>? MVrJR|UxRTVibl2= NXrST2I4OjN6NESwN|g>
YUMAC MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknuNVAh|ryP NX6zSotlPzJiaB?= MXrEUXNQ M3T1OGlEPTB;NTDuUS=> NVW3UnR7OjN6NESwN|g>
OV-90 M3S5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTKNVAh|ryP M1jhclczKGh? M{jHN2ROW09? MoezTWM2OD1{OTDuUS=> Mo\zNlM5PDRyM{i=
NCI-H508 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHGNVAh|ryP NF\EZ284OiCq M1XYN2ROW09? NX7ZcWlvUUN3ME2xNEDPxE1? MX:yN|g1PDB|OB?=
MDA-MB-231 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vHVVExKM7:TR?= NVT2OHI2PzJiaB?= M1PjTGROW09? MW\JR|UxRTFyIN88US=> NYizcYRwOjN6NESwN|g>
SW756 M1X6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LYTVExKM7:TR?= MnjFO|IhcA>? MmrmSG1UVw>? NVizeINRUUN3ME2xNEDPxE1? M2Ls[lI{QDR2MEO4
SW-837 MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j0RVExKM7:TR?= NIT0RnU4OiCq NX:1TpB4TE2VTx?= M4rWdGlEPTB;MUCg{txO Moq1NlM5PDRyM{i=
UMUC-3 M3HSbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxNEDPxE1? MVy3NkBp NGrVPHFFVVOR MmPFTWM2OD1zMDFOwG0> MVqyN|g1PDB|OB?=
LS-174T M4OwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nqUVExKM7:TR?= M2PDVFczKGh? MlrMSG1UVw>? Mmq0TWM2OD1zMDFOwG0> MXGyN|g1PDB|OB?=
A549 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? MnjEO|IhcA>? MkCwSG1UVw>? MnPETWM2OD1zMDFOwG0> NUPUTmF6OjN6NESwN|g>
SHP-77 M4n0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\oNVAh|ryP M4nnOVczKGh? NIPqOXZFVVOR NXnhcXB3UUN3ME2xNEDPxE1? NHe0OGIzOzh2NECzPC=>
SW480 M2TqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3L3flExKM7:TR?= NGLrZ4M4OiCq MmewSG1UVw>? NHvLPHJKSzVyPUGwJO69VQ>? MljWNlM5PDRyM{i=
DLD-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0UVExKM7:TR?= Mlm1O|IhcA>? MYLEUXNQ MYnJR|UxRTFyIN88US=> MnTlNlM5PDRyM{i=
HCT-116 NX3zc2VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;1[G4yOCEQvF2= M4\ScFczKGh? M37jcmROW09? M3jzcWlEPTB;MUCg{txO MkC0NlM5PDRyM{i=
NCI-H747 M4exSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nmd|ExKM7:TR?= NGiyUnY4OiCq MXPEUXNQ M3rxN2lEPTB;MUCg{txO MWOyN|g1PDB|OB?=
T-84 M2DkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuxNEDPxE1? NFjVZ4Q4OiCq NXHr[|Y3TE2VTx?= M2K4fmlEPTB;MUCg{txO MXiyN|g1PDB|OB?=
NCI-H460 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHKNVAh|ryP Mme0O|IhcA>? MWnEUXNQ M1;mPGlEPTB;MUCg{txO M{nKU|I{QDR2MEO4
Calu-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonoNVAh|ryP NV7BSVBRPzJiaB?= NGPNN5VFVVOR MV7JR|UxRTFyIN88US=> NWfXRodbOjN6NESwN|g>
HCC-2998 NUDt[ld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHONG8yOCEQvF2= M3TmcVczKGh? MXTEUXNQ MoHSTWM2OD1zMDFOwG0> NXS0eWcxOjN6NESwN|g>
LS1034 Mmq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrtS4UyOCEQvF2= M3;4UFczKGh? MkjISG1UVw>? NUPEeW9oUUN3ME2xNEDPxE1? MmmyNlM5PDRyM{i=
CHP-212 NXTlfIliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L6bVExKM7:TR?= MlTRO|IhcA>? NYCz[XdJTE2VTx?= NFXpbohKSzVyPUGwJO69VQ>? M3;JPVI{QDR2MEO4
SK-N-AS MmraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVexNEDPxE1? MljBO|IhcA>? M13aNGROW09? MnrGTWM2OD1zMDFOwG0> MmS4NlM5PDRyM{i=
BFTC-905 NFjRWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi3bZoyOCEQvF2= M17IZ|czKGh? NWX0OJJ3TE2VTx?= NFjyWHdKSzVyPUGwJO69VQ>? MV6yN|g1PDB|OB?=
HuT78 NX3zRlVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nJZlExKM7:TR?= NE\yWnc4OiCq M2H0cGROW09? NYHENZV5UUN3ME21NkBvVQ>? MmL2NlM5PDRyM{i=
RPMI-8226 NWrSe4xIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTJUXQyOCEQvF2= MXS3NkBp NVjEUHRwTE2VTx?= M3vSSGlEPTB;Mk[zJI5O M4G0e|I{QDR2MEO4
BC-3 M1H3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOxNEDPxE1? MUG3NkBp M1vtdmROW09? NXjQV2N7UUN3ME2yO|chdk1? NIfoXJIzOzh2NECzPC=>
ACHN Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjhfmNQOTBizszN NGLlcpk4OiCq MkGzSG1UVw>? MUnJR|UxRTJ7NDDuUS=> MXSyN|g1PDB|OB?=
JRT3-T35 NHHWcXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDBNVAh|ryP MnvtO|IhcA>? NFfxOJZFVVOR M4Phc2lEPTB;Mkm1JI5O NX3VNHNjOjN6NESwN|g>
SK-MES-1 NFS5VVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv3NVAh|ryP MYO3NkBp M4HMNGROW09? MoH6TWM2OD1|Mkmgcm0> MV:yN|g1PDB|OB?=
CESS M4XMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWGxNEDPxE1? MVe3NkBp NHPVVXpFVVOR MluwTWM2OD12OUegcm0> MUmyN|g1PDB|OB?=
H4 NI\2eFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjTTVZOOTBizszN NVW2V3BnPzJiaB?= MWrEUXNQ Mmr0TWM2OD14MUmgcm0> MYWyN|g1PDB|OB?=
BC-1 NH;UZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUexNEDPxE1? NUXpSJFMPzJiaB?= NH7NXodFVVOR NF3FWllKSzVyPUewOEBvVQ>? MX[yN|g1PDB|OB?=
DB MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrkWHY5OTBizszN MYS3NkBp NGD6ZWhFVVOR MVrJR|UxRTh5MzDuUS=> NFX5c4szOzh2NECzPC=>
RPMI-6666 Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDBUZBjOTBizszN M1H5dlczKGh? NFnhRlNFVVOR MYjJR|UxRTl{ODDuUS=> M2X1c|I{QDR2MEO4
MC/CAR NUXON|RJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[wRZpvOTBizszN NUTUVZlKPzJiaB?= NHPWW41FVVOR NFLZbJpKSzVyPUGuNFAzKM7:TR?= MX2yN|g1PDB|OB?=
SNU-1 NXjlfIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwNVAh|ryP M3rtblczKGh? NUi2UGJJTE2VTx?= MUPJR|UxRTFwNUCxJO69VQ>? NWfRfWxFOjN6NESwN|g>
CEM/C1 NYqwcoxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PzXFExKM7:TR?= MmTYO|IhcA>? MYDEUXNQ M4H4SmlEPTB;MT63O|Mh|ryP M{DEOlI{QDR2MEO4
GDM-1 M{jZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW3XIcyOCEQvF2= NFPpOIo4OiCq MYHEUXNQ NGrCfXlKSzVyPUGuPVk4KM7:TR?= M1LtNVI{QDR2MEO4
HT-1080 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi2NVAh|ryP M1nPZVczKGh? M3T0UmROW09? MYfJR|UxRTJwMEC0JO69VQ>? NIrzSGgzOzh2NECzPC=>
HL-60 NHfvTlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXDNVAh|ryP NIjudJM4OiCq NVnPcG9CTE2VTx?= NYXscldRUUN3ME2yMlE4QCEQvF2= Mm\nNlM5PDRyM{i=
C3A MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorkNVAh|ryP M{PnO|czKGh? MYPEUXNQ M1f6NmlEPTB;NT60NVQh|ryP MmrpNlM5PDRyM{i=
MES-SA NFvUc|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVKxNEDPxE1? M4jFUVczKGh? NVn3THVXTE2VTx?= MXrJR|UxRTZwOUi5JO69VQ>? MWiyN|g1PDB|OB?=
22Rv1 NGfi[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfUW2QyOCEQvF2= NX62UYxoPzJiaB?= MWDEUXNQ MWjJR|UxRTFyIN88US=> MYmyN|g1PDB|OB?=
647-V MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzsb5YyOCEQvF2= MUm3NkBp NFy3PYNFVVOR NX7pN4IyUUN3ME2xNEDPxE1? M2DsUlI{QDR2MEO4
786-O NVrwb2c4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZZYo1OTBizszN NEjNcHA4OiCq MWrEUXNQ M{XHSWlEPTB;MUCg{txO NUHoXnRZOjN6NESwN|g>
A172 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\zNVAh|ryP NYD2[|dKPzJiaB?= NETE[IpFVVOR NHXETFBKSzVyPUGwJO69VQ>? Ml\JNlM5PDRyM{i=
A204 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\WNVAh|ryP M1TC[|czKGh? MkHPSG1UVw>? NET0VINKSzVyPUGwJO69VQ>? NYr2TZR2OjN6NESwN|g>
A427 M1:5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm1dIgyOCEQvF2= M2fWWVczKGh? MXrEUXNQ NYn6b5J4UUN3ME2xNEDPxE1? NH33PFkzOzh2NECzPC=>
A431 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlewNVAh|ryP NXO1fFBMPzJiaB?= NYHzfGdQTE2VTx?= NEjne3pKSzVyPUGwJO69VQ>? NXTSdYNFOjN6NESwN|g>
A2780 Mn7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XJbVExKM7:TR?= NHn2V5c4OiCq MVjEUXNQ M4G2O2lEPTB;MUCg{txO M135OVI{QDR2MEO4
ARH-77 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnvTYMyOCEQvF2= MYq3NkBp M3LyT2ROW09? NGPvNIRKSzVyPUGwJO69VQ>? NIPre4wzOzh2NECzPC=>
Be(2)C NVzxV4I3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH1SmMyOCEQvF2= MX:3NkBp NYfPUVA6TE2VTx?= MV\JR|UxRTFyIN88US=> NYi4WY5oOjN6NESwN|g>
BT-20 NVTJZotMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLHVopLOTBizszN NYnJO4wzPzJiaB?= NX;HXI9iTE2VTx?= NVn4eXVlUUN3ME2xNEDPxE1? NIT2XoQzOzh2NECzPC=>
BxPc3 M{HETGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUCxNEDPxE1? MmjFO|IhcA>? M{nEU2ROW09? MlvyTWM2OD1zMDFOwG0> NYiwWoprOjN6NESwN|g>
C-4 I NVvWepJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PDZVExKM7:TR?= MWq3NkBp NGXSSYtFVVOR NXnvUpVjUUN3ME2xNEDPxE1? MYCyN|g1PDB|OB?=
C33A MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojMNVAh|ryP NHvFdo04OiCq MVzEUXNQ M1q0TmlEPTB;MUCg{txO MofQNlM5PDRyM{i=
CAL-27 NXn5UGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNEDPxE1? MX63NkBp NESxOJFFVVOR MkT4TWM2OD1zMDFOwG0> Mnj1NlM5PDRyM{i=
CAL-62 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmftNVAh|ryP M1PwR|czKGh? M{\MfWROW09? NUTRSYpnUUN3ME2xNEDPxE1? MlP5NlM5PDRyM{i=
Calu-3 NFjWfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX6xNEDPxE1? NU\MUVNKPzJiaB?= MXfEUXNQ NIjBb3FKSzVyPUGwJO69VQ>? Mnz3NlM5PDRyM{i=
CaOV3 M{LHOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TiUVExKM7:TR?= NF7EOYo4OiCq M1TXdWROW09? NVK3WXdzUUN3ME2xNEDPxE1? M3rSeVI{QDR2MEO4
CGTHW1 NH:zfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DtblExKM7:TR?= MlXuO|IhcA>? NYXMbY5kTE2VTx?= MlXiTWM2OD1zMDFOwG0> NH;v[nozOzh2NECzPC=>
CHL-1 NEXrOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyxNEDPxE1? MnPDO|IhcA>? M33QdGROW09? M37Ud2lEPTB;MUCg{txO MXGyN|g1PDB|OB?=
Colo320DM NHfGeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxNEDPxE1? MlvvO|IhcA>? MlnqSG1UVw>? MVrJR|UxRTFyIN88US=> MmL4NlM5PDRyM{i=
Colo704 NXr5d4FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mXHcyOCEQvF2= NXHnc5dDPzJiaB?= MX;EUXNQ M1rMS2lEPTB;MUCg{txO M4TSN|I{QDR2MEO4
COR-L23 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVOxNEDPxE1? MkLvO|IhcA>? MYrEUXNQ M2WweGlEPTB;MUCg{txO MoDFNlM5PDRyM{i=
CRO-AP2 NGW4TVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;6WoxEOTBizszN M4LDWFczKGh? NWn3Tmh4TE2VTx?= MWjJR|UxRTFyIN88US=> MXWyN|g1PDB|OB?=
Daudi M2W2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjSdHlTOTBizszN M1nMelczKGh? NVLZOmZNTE2VTx?= MYfJR|UxRTFyIN88US=> M{jjcFI{QDR2MEO4
DOTC 24510 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSxNEDPxE1? NVrR[IhGPzJiaB?= M1XQRmROW09? MYXJR|UxRTFyIN88US=> MoHaNlM5PDRyM{i=
DU-145 NFyzZVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLyeXdMOTBizszN MVO3NkBp NFnCcJlFVVOR NUDKZXpCUUN3ME2xNEDPxE1? NXHJSppyOjN6NESwN|g>
EB-3 M3LuXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnHeFFDOTBizszN MV:3NkBp MUjEUXNQ NWOyWFZMUUN3ME2xNEDPxE1? NVzsVpVROjN6NESwN|g>
EFM-19 NGHVdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXndG4yOCEQvF2= NF3nPYQ4OiCq MV\EUXNQ M3;IO2lEPTB;MUCg{txO MVuyN|g1PDB|OB?=
EKVX MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;2TlExKM7:TR?= M3;uW|czKGh? NVzNbohuTE2VTx?= NF\CWZJKSzVyPUGwJO69VQ>? M1rCOVI{QDR2MEO4
FaDu Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfuTFUyOCEQvF2= MkDWO|IhcA>? NX\PVI9jTE2VTx?= NF\ueGFKSzVyPUGwJO69VQ>? MUSyN|g1PDB|OB?=
G401 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xNEDPxE1? MWm3NkBp NFHZdoNFVVOR Mo\YTWM2OD1zMDFOwG0> NFWwfpUzOzh2NECzPC=>
HCC-70 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7seGRmOTBizszN NIriOnk4OiCq NXfhdYJKTE2VTx?= NFv1dXVKSzVyPUGwJO69VQ>? MkLENlM5PDRyM{i=
HCC-1954 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHm5NHYyOCEQvF2= NX7PdHpbPzJiaB?= MlzMSG1UVw>? M1TOXmlEPTB;MUCg{txO MlG3NlM5PDRyM{i=
Hela NXzQdGNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxNEDPxE1? NGj2NFQ4OiCq MlnZSG1UVw>? MkfRTWM2OD1zMDFOwG0> MUWyN|g1PDB|OB?=
Hep3B MmPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vzXVExKM7:TR?= MUK3NkBp NVnCSlVkTE2VTx?= NVHNOZFvUUN3ME2xNEDPxE1? M{ntdFI{QDR2MEO4
HMCB NH\vSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULpVGVyOTBizszN NX\PXJFMPzJiaB?= M17xNGROW09? NFrQZ2RKSzVyPUGwJO69VQ>? NELJVVczOzh2NECzPC=>
HN5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETJTIwyOCEQvF2= NFfURpA4OiCq M4\nUmROW09? Mn3UTWM2OD1zMDFOwG0> MV2yN|g1PDB|OB?=
HOS MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX6xNEDPxE1? NGrmSIE4OiCq M{\WO2ROW09? NILpTGhKSzVyPUGwJO69VQ>? NFHQXGMzOzh2NECzPC=>
HPAF-II MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH0e28yOCEQvF2= NH25WYg4OiCq M3uwd2ROW09? MmfoTWM2OD1zMDFOwG0> NVOwdlRJOjN6NESwN|g>
Hs746.T MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjTpEyOCEQvF2= MWK3NkBp M1zSb2ROW09? NXLheZdlUUN3ME2xNEDPxE1? M4q2UlI{QDR2MEO4
HT M1jEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexNEDPxE1? M3nIdlczKGh? MljGSG1UVw>? NXXlTpZTUUN3ME2xNEDPxE1? NF;mWlkzOzh2NECzPC=>
HT-3 M2[2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\0VGdzOTBizszN NWnHPJVrPzJiaB?= NV7ubZJnTE2VTx?= M17lOmlEPTB;MUCg{txO MlLyNlM5PDRyM{i=
HuNS-1 NE\ZU29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDrZ4dTOTBizszN NFnDdlY4OiCq NYf0XpZMTE2VTx?= MoK4TWM2OD1zMDFOwG0> NWLrcVVxOjN6NESwN|g>
IGROV1 NVTDRWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzzfVYyOCEQvF2= NF3WNoY4OiCq NYDkd5VjTE2VTx?= NI\NWplKSzVyPUGwJO69VQ>? Mn6yNlM5PDRyM{i=
J82 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH1NVAh|ryP MXe3NkBp NGrVbWhFVVOR M1L0VmlEPTB;MUCg{txO MkjRNlM5PDRyM{i=
JM1 M3Lvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHX3fo8yOCEQvF2= MXG3NkBp NYXxfJhyTE2VTx?= M2rmbmlEPTB;MUCg{txO NGKyWYozOzh2NECzPC=>
Kato III M{HoR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rDNFExKM7:TR?= NHjJVo44OiCq M1r0WmROW09? NVqzW4ljUUN3ME2xNEDPxE1? NFTaPIgzOzh2NECzPC=>
KHOS-240S NIPjWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\aU4dROTBizszN NHe3bVY4OiCq MX3EUXNQ MYjJR|UxRTFyIN88US=> M1PKflI{QDR2MEO4
KM-12 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGyfIdnOTBizszN NEjlR2Y4OiCq NXL4WJE5TE2VTx?= NHXONolKSzVyPUGwJO69VQ>? M4rh[|I{QDR2MEO4
KPL-1 NWmyUGxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLxPXUyOCEQvF2= MV23NkBp Ml\iSG1UVw>? NV3Ze4ZDUUN3ME2xNEDPxE1? MnjnNlM5PDRyM{i=
KYSE-30 NFrNOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxNEDPxE1? Mkf2O|IhcA>? NFPNVmZFVVOR MV3JR|UxRTFyIN88US=> MlzwNlM5PDRyM{i=
LNCaP NGO4U5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXTe3pZOTBizszN NF[3[mI4OiCq M1W1cmROW09? NVzuVZl6UUN3ME2xNEDPxE1? MlXINlM5PDRyM{i=
MCF-7 NWLtWpI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5N|ExKM7:TR?= MkPvO|IhcA>? NITUVYpFVVOR M{jJW2lEPTB;MUCg{txO M2nyeVI{QDR2MEO4
MC-IXC NHLNVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jhd|ExKM7:TR?= MUO3NkBp MVfEUXNQ NWf4NI8yUUN3ME2xNEDPxE1? NG[2fYQzOzh2NECzPC=>
MDA-MB-175 VII NEj0T|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHwNVAh|ryP MUG3NkBp M4jGfWROW09? NYPG[Ho1UUN3ME2xNEDPxE1? M1fQPVI{QDR2MEO4
MDA-MB-468 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LHd|ExKM7:TR?= M{Pme|czKGh? MmnqSG1UVw>? MVLJR|UxRTFyIN88US=> NHzyS4gzOzh2NECzPC=>
MiaPaCa NV3BfXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWzNVAh|ryP MoTZO|IhcA>? NFy1b41FVVOR NEnPbXpKSzVyPUGwJO69VQ>? NUW3cJlNOjN6NESwN|g>
Molt-4 NXLwdXJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGCy[3cyOCEQvF2= NXyyOWwxPzJiaB?= NYr3[pVLTE2VTx?= NWTs[GxqUUN3ME2xNEDPxE1? NF33VXAzOzh2NECzPC=>
NCI-ADR/RES NFHEeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXVNVAh|ryP MmrXO|IhcA>? NHe0cZFFVVOR MYfJR|UxRTFyIN88US=> MX6yN|g1PDB|OB?=
NCI-H69 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{npV|ExKM7:TR?= MkfIO|IhcA>? MWXEUXNQ M13J[2lEPTB;MUCg{txO MkftNlM5PDRyM{i=
NCI-H82 NW[2doJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVy2fFg2OTBizszN NIHrc2I4OiCq Ml7TSG1UVw>? MWTJR|UxRTFyIN88US=> M1rReFI{QDR2MEO4
NCI-N87 MlLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKxNEDPxE1? MkjDO|IhcA>? M2HWbWROW09? NVfLfVRKUUN3ME2xNEDPxE1? M4DOO|I{QDR2MEO4
NCI-H146 NX;lPGNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PkVVExKM7:TR?= NYHESHZUPzJiaB?= NVPQb24xTE2VTx?= MnjFTWM2OD1zMDFOwG0> MV6yN|g1PDB|OB?=
NCI-H157 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP3fJB3OTBizszN Mo\WO|IhcA>? M1PIOmROW09? NHH0UZZKSzVyPUGwJO69VQ>? MlXNNlM5PDRyM{i=
NCI-H187 M{W0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLGNVAh|ryP M1PvSFczKGh? MlriSG1UVw>? NIjBbFNKSzVyPUGwJO69VQ>? MYmyN|g1PDB|OB?=
NCI-H209 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfmfZAyOCEQvF2= NFrmdGk4OiCq NGjaTYRFVVOR MmPOTWM2OD1zMDFOwG0> M2jLbFI{QDR2MEO4
NCI-H226 M4H6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7NNVAh|ryP NGfaN5Y4OiCq NEjncGRFVVOR MmTmTWM2OD1zMDFOwG0> Ml7ONlM5PDRyM{i=
NCI-H292 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXqNVAh|ryP M1S4clczKGh? NUX3ZVRnTE2VTx?= MkLNTWM2OD1zMDFOwG0> MXWyN|g1PDB|OB?=
NCI-H322 NVPJWodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\6Z|B4OTBizszN M1jpWVczKGh? NGTCTG5FVVOR MX7JR|UxRTFyIN88US=> M1zTTFI{QDR2MEO4
NCI-H358 M1K3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxNEDPxE1? MVi3NkBp M{W5cmROW09? MorQTWM2OD1zMDFOwG0> NFvYfFAzOzh2NECzPC=>
NCI-H520 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TCVFExKM7:TR?= M3PZO|czKGh? MlrISG1UVw>? MX\JR|UxRTFyIN88US=> MUSyN|g1PDB|OB?=
NCI-H526 NXOy[XAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jsNFExKM7:TR?= M4O5cVczKGh? NFjKflNFVVOR M1LEXWlEPTB;MUCg{txO MVGyN|g1PDB|OB?=
NCI-H630 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTRT4QyOCEQvF2= NET1VWM4OiCq NVrp[ZJOTE2VTx?= MUHJR|UxRTFyIN88US=> M3n0[FI{QDR2MEO4
NCI-H661 NXS2N|lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n4c|ExKM7:TR?= MWG3NkBp MXTEUXNQ MULJR|UxRTFyIN88US=> M1W3flI{QDR2MEO4
NCI-H716 M3PvU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;wVFExKM7:TR?= M{fvZ|czKGh? MYDEUXNQ NYPuNG5CUUN3ME2xNEDPxE1? MVeyN|g1PDB|OB?=
NCI-H1563 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYG5PY1zOTBizszN NHnubGU4OiCq NIrsUG9FVVOR MULJR|UxRTFyIN88US=> MlL6NlM5PDRyM{i=
NCI-H1792 NEW1R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0NVAh|ryP NFvLPWQ4OiCq MWXEUXNQ M2ns[2lEPTB;MUCg{txO M{\RVlI{QDR2MEO4
NCI-H2030 M{PIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX6xNEDPxE1? MWO3NkBp NHzlWnRFVVOR MlGxTWM2OD1zMDFOwG0> M2DrW|I{QDR2MEO4
NCI-H2052 NVTnU|Q3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvZNVAh|ryP MlzCO|IhcA>? NGDDSVJFVVOR MY\JR|UxRTFyIN88US=> Mnz4NlM5PDRyM{i=
NCI-H2122 NFL6bpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17DVlExKM7:TR?= NFXoSIo4OiCq M1TTWmROW09? MXzJR|UxRTFyIN88US=> MVuyN|g1PDB|OB?=
NCI-H2228 NWP2R29ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYWxNEDPxE1? NHPZSYw4OiCq Mkj0SG1UVw>? M3HHd2lEPTB;MUCg{txO M{n0T|I{QDR2MEO4
OE-19 M4DkdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4b4VIOTBizszN MVe3NkBp MVfEUXNQ MYfJR|UxRTFyIN88US=> MkDrNlM5PDRyM{i=
OE-21 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rEW|ExKM7:TR?= M3W2dVczKGh? NF;VOphFVVOR Mlu5TWM2OD1zMDFOwG0> M4[0VVI{QDR2MEO4
OE-33 M3y2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP4TFAyOCEQvF2= NYm2dFlKPzJiaB?= NHvmXHlFVVOR NVXkcoJwUUN3ME2xNEDPxE1? MlXhNlM5PDRyM{i=
OVCAR-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TzOVExKM7:TR?= MoLQO|IhcA>? NIrhNYdFVVOR NGPFPIpKSzVyPUGwJO69VQ>? NVfqXGpDOjN6NESwN|g>
OVCAR-4 NYDEVmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3iSVRiOTBizszN NVrpSWlRPzJiaB?= MVvEUXNQ NXjuRo02UUN3ME2xNEDPxE1? MkW4NlM5PDRyM{i=
OVCAR-5 MoPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnSyNVAh|ryP NIfPOXo4OiCq NX2zSlRLTE2VTx?= M2myemlEPTB;MUCg{txO NIPFZYIzOzh2NECzPC=>
P3HR-1 M4Lkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mom4NVAh|ryP M3f3eFczKGh? MmjFSG1UVw>? MULJR|UxRTFyIN88US=> MlnlNlM5PDRyM{i=
PC-3 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXxRolIOTBizszN MVe3NkBp NX7KZ|FmTE2VTx?= M1HCdWlEPTB;MUCg{txO NELIToszOzh2NECzPC=>
Raji MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHZNVAh|ryP NGHnflI4OiCq NXn1[Gp7TE2VTx?= MmPjTWM2OD1zMDFOwG0> M2XxT|I{QDR2MEO4
RD MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmxNEDPxE1? MX63NkBp NUL5b|VRTE2VTx?= M2frbWlEPTB;MUCg{txO MnnYNlM5PDRyM{i=
RD-ES MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3BZYwyOCEQvF2= NXPGWYk1PzJiaB?= NWTWd49OTE2VTx?= NFP5bVhKSzVyPUGwJO69VQ>? M3\NclI{QDR2MEO4
RL MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHHcoNmOTBizszN MYO3NkBp NUCwOXlGTE2VTx?= NG\Yd4RKSzVyPUGwJO69VQ>? NV;XdoY1OjN6NESwN|g>
SaOS2 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\DNVAh|ryP NIjSdGg4OiCq MkjjSG1UVw>? MnHMTWM2OD1zMDFOwG0> NHKyOG0zOzh2NECzPC=>
SCC-9 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLIUnQyOCEQvF2= MmXhO|IhcA>? NVPL[odvTE2VTx?= NITKWpZKSzVyPUGwJO69VQ>? M4D4[FI{QDR2MEO4
SCC-12 NFH2dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rUNFExKM7:TR?= NX\EfW1MPzJiaB?= MljKSG1UVw>? NUHoT|RIUUN3ME2xNEDPxE1? MVSyN|g1PDB|OB?=
SCC-13 NWXHXXRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnMeGEyOCEQvF2= MonYO|IhcA>? MnS0SG1UVw>? NYTqRZBVUUN3ME2xNEDPxE1? NEPhfpQzOzh2NECzPC=>
SCC-15 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzZNVAh|ryP NHfFW3U4OiCq NVHIVppOTE2VTx?= NGLk[FBKSzVyPUGwJO69VQ>? M4[2WlI{QDR2MEO4
SCC-25 M2LPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXPUm0yOCEQvF2= MkLLO|IhcA>? NH61dG5FVVOR NUH6XVh{UUN3ME2xNEDPxE1? NV7wO|NXOjN6NESwN|g>
SCLC-3 NILUb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnENVAh|ryP MYi3NkBp Mkn0SG1UVw>? NYfCOVJyUUN3ME2xNEDPxE1? NX[0WGdpOjN6NESwN|g>
SF-268 NFnW[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LCWlExKM7:TR?= MmHJO|IhcA>? NFvEXYdFVVOR NV3yc4JJUUN3ME2xNEDPxE1? M3nTNlI{QDR2MEO4
SF-295 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLJNVAh|ryP NY\QNIE3PzJiaB?= NYf2UpA5TE2VTx?= NXfYZXRrUUN3ME2xNEDPxE1? NHTM[HQzOzh2NECzPC=>
SJRH30 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy5Rm0yOCEQvF2= MXW3NkBp NV;OSFZNTE2VTx?= NWPtc3NlUUN3ME2xNEDPxE1? M2XHdlI{QDR2MEO4
SK-BR-3 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUGxNEDPxE1? NH;jSXI4OiCq Mon1SG1UVw>? NVvPRncxUUN3ME2xNEDPxE1? M{DkWVI{QDR2MEO4
SK-LMS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33BclExKM7:TR?= NHTLT|g4OiCq NF;pXFNFVVOR NUPJO5VKUUN3ME2xNEDPxE1? MY[yN|g1PDB|OB?=
SK-N-DZ MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\M[JI{OTBizszN MmDOO|IhcA>? NGjG[IZFVVOR NGexTo1KSzVyPUGwJO69VQ>? MWmyN|g1PDB|OB?=
SK-N-F1 MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlywNVAh|ryP NYqxUnVPPzJiaB?= MXPEUXNQ NWjQTolxUUN3ME2xNEDPxE1? MYqyN|g1PDB|OB?=
SKOV-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWGxNEDPxE1? M{HIPVczKGh? M1iweWROW09? M2rhU2lEPTB;MUCg{txO NFW5VIMzOzh2NECzPC=>
SK-UT-1 NYPSb3dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVuxNEDPxE1? NGLpNFE4OiCq MnvSSG1UVw>? MlHFTWM2OD1zMDFOwG0> MVGyN|g1PDB|OB?=
SN12C MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfZWIIyOCEQvF2= MkHyO|IhcA>? M3PNfWROW09? MVLJR|UxRTFyIN88US=> NVnITIlpOjN6NESwN|g>
SNB-19 NW\1cZRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjhO3VIOTBizszN M1zLZVczKGh? NWD3XWlrTE2VTx?= MoPXTWM2OD1zMDFOwG0> MnfLNlM5PDRyM{i=
SNU-5 M4G4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;NUVExKM7:TR?= MnzxO|IhcA>? MXfEUXNQ NWf4Spg5UUN3ME2xNEDPxE1? M2[1d|I{QDR2MEO4
SNU-16 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWzXWgyOCEQvF2= M1XKUVczKGh? NYHqdWdtTE2VTx?= NIL6c|JKSzVyPUGwJO69VQ>? NXiwRnFGOjN6NESwN|g>
SNU-398 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj4[Xl2OTBizszN MnmwO|IhcA>? NUPWfpliTE2VTx?= MnTETWM2OD1zMDFOwG0> M{jTdFI{QDR2MEO4
SNU-449 NGrCZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLlTlkyOCEQvF2= M{O3V|czKGh? NVf4PWlOTE2VTx?= MVTJR|UxRTFyIN88US=> M4n2dlI{QDR2MEO4
SR NW\xVFh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVSz[GRnOTBizszN NWPrU2JCPzJiaB?= Mn3kSG1UVw>? MoHXTWM2OD1zMDFOwG0> M17HVlI{QDR2MEO4
ST486 M4jFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\q[VQzOTBizszN NEL1flA4OiCq M3PGZ2ROW09? NHzmU5BKSzVyPUGwJO69VQ>? NFPYNVYzOzh2NECzPC=>
SW579 M1vS[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC2NVAh|ryP MWC3NkBp Mnm1SG1UVw>? NXTJN5Y3UUN3ME2xNEDPxE1? MoXiNlM5PDRyM{i=
SW684 NGrJWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH4OVF3OTBizszN MV63NkBp MXHEUXNQ NHPYVWNKSzVyPUGwJO69VQ>? M2rsOFI{QDR2MEO4
SW-780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqxNEDPxE1? MlvEO|IhcA>? NUHTOnBqTE2VTx?= MnHzTWM2OD1zMDFOwG0> NVLwUXdbOjN6NESwN|g>
SW900 NGHPXGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXmxNEDPxE1? M2jlWFczKGh? MXnEUXNQ NYnZboJ6UUN3ME2xNEDPxE1? NYPFcFF4OjN6NESwN|g>
SW1088 MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnWNVAh|ryP M3z4OlczKGh? NH[wV2hFVVOR NFPYN4JKSzVyPUGwJO69VQ>? MXGyN|g1PDB|OB?=
SW1463 NH\SeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHMWo9XOTBizszN MUe3NkBp NX3sZmVVTE2VTx?= M{WxRWlEPTB;MUCg{txO NX\EN5ZoOjN6NESwN|g>
SW1990 NYDRRpJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LhdFExKM7:TR?= Mn7SO|IhcA>? NHfrcHdFVVOR Ml\WTWM2OD1zMDFOwG0> NV3MV5RjOjN6NESwN|g>
T47D M{jXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNEDPxE1? MVK3NkBp NXjiWHZwTE2VTx?= NHT1RY9KSzVyPUGwJO69VQ>? MkPWNlM5PDRyM{i=
TE381.T M1n4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HkPFExKM7:TR?= M3:5UlczKGh? NXfJS49JTE2VTx?= MXfJR|UxRTFyIN88US=> MonlNlM5PDRyM{i=
TK-10 M4TjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrucFEyOCEQvF2= M{mxT|czKGh? M3jSfGROW09? NXfzbI1qUUN3ME2xNEDPxE1? MlfmNlM5PDRyM{i=
U2OS M{fD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO5S4VkOTBizszN Mlf0O|IhcA>? M3zVdmROW09? MVjJR|UxRTFyIN88US=> MoPJNlM5PDRyM{i=
U251 M3nTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3z0d|ExKM7:TR?= NYrtSnlsPzJiaB?= MXvEUXNQ NFG5WJhKSzVyPUGwJO69VQ>? MkL0NlM5PDRyM{i=
UACC-812 NVjIR3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK3NVAh|ryP NH\z[Xc4OiCq M1L4Z2ROW09? M1HSVWlEPTB;MUCg{txO NGfxdIEzOzh2NECzPC=>
YAPC MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2xNEDPxE1? NEP3Zpo4OiCq NFy0ZZZFVVOR NF7NbnZKSzVyPUGwJO69VQ>? MVWyN|g1PDB|OB?=
ZR-75-1 M3PrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHjRWcyOCEQvF2= M{i0VlczKGh? MWPEUXNQ M{O0OmlEPTB;MUCg{txO NVzvfFNsOjN6NESwN|g>
A375 NWraNGd2TnWwY4Tpc44h[XO|YYm= M{PK[FEvOiEQvF2= NF7sd4I1KGh? MWfEUXNQ M4K3PWlvcGmkaYTpc44hd2ZicHjvd5Bpd3K7bHH0bY9vKG:oIF3FT{whTVKNLDDhcoQhWz[S NWS4e5dUOjJ|OEm0O|E>
YUSIT1 M{jTVmZ2dmO2aX;uJIF{e2G7 MkXpSG1UVw>? MYHy[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0> MlzWNlI{QDl2N{G=
MeWo NE[2UGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX3EUXNQ NGDKSZRKSzVyIE2gPVg4KG6P MXyyOlAyQDV{NB?=
WiDr M2ixR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUTwV4FVTE2VTx?= NVLqWGtKUUN3MDC9JFc3KG6P M2PXVlI3ODF6NUK0
Colo-205 NXrOcoZpTnWwY4Tpc44h[XO|YYm= M4m1RlEh|ryP MUC0JIQ> NIPmZ41FVVOR MUTJcoR2[2WmIHGgbIlocGy7IHPvcZBiemGkbHWgZ49ueGGldHnvckBxcGWwb4T5dIU> NIn3VVMzPTN6MUG1Ni=>
RBW-1 NXf4TXdJTnWwY4Tpc44h[XO|YYm= M1\WcVEh|ryP NYDjOmZ[TE2VTx?= MnLOUo8hemWmdXP0bY9vKG:oIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v NEG1ZXkzPDh6NU[5NC=>
RBO-1 M32ze2Z2dmO2aX;uJIF{e2G7 NYnCZlExOSEQvF2= MW\EUXNQ NWfUXopQUW6qaXLpeIlwdiCxZjDN[YshOS9{IIDoc5NxcG:{eXzheIlwdg>? NF35dWszPDh6NU[5NC=>
RBO-2 MlqwSpVv[3Srb36gZZN{[Xl? M1HrdVEh|ryP M{DBZmROW09? M{fo[mlvcGmkaYTpc44hd2ZiIF3lb{AyNzJicHjvd5Bpd3K7bHH0bY9v MVqyOFg5PTZ7MB?=
RBOW M2C3e2Z2dmO2aX;uJIF{e2G7 NELhZ2kyKM7:TR?= NHrwOGlFVVOR Mn:xTY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44> M1L5VFI1QDh3Nkmw
M257 NFvkeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWixNFAhdk1? MlrhO|IhcA>? M4rBcmRw\XNibn;0JIlvcGmkaYSgdJJwdGmoZYLheIlwdiCxZjDNNlU4KGOnbHygbIFz[m:3cnnu[{B4cWymIIT5dIUhSlKDRh?= Mnz5NlM{OTd2NE[=
LCP MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWxNFAhdk1? NXrDNXo2PzJiaB?= MVPJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhVEOSIHPlcIwhcGG{Yn;1dolv\yCEUlHGJHY3ODCUIH31eIFvfGG2aX;u MWiyN|MyPzR2Nh?=
WM266 MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HCeFExOCCwTR?= NFfKfJM4OiCq M4Trd2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckBw\iCZTUK2OkBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCxSEBufXSjboTheIlwdg>? NE\lSJczOzNzN{S0Oi=>
M257 M2DZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESzTnMyODBibl2= NYXZeHhIPzJiaB?= NHj2SGFFd2W|IH7veEBqdmirYnn0JGVTUzFvMjDwbI9{eGixconsZZRqd25iaX6gUVI2PyClZXzsJIhiemKxdYLpcochf2muZDD0fZBmKEKUQV[= M{HN[lI{OzF5NES2
LCP NH7KNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDaNVAxKG6P NVrL[XNCPzJiaB?= MWXJcohq[mm2IFXST|EuOiCyaH;zdIhwenmuYYTpc44hcW5iTFPQJINmdGxiaHHyZo92emmwZzDCVmFHKFZ4MEDSJI12fGGwdHH0bY9v MlTrNlM{OTd2NE[=
WM266 NGrMVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLKNVAxKG6P NX3xfW01PzJiaB?= M{ewPWlvcGmkaYSgSXJMOS1{IIDoc5NxcG:{eXzheIlwdiCrbjDXUVI3PiClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxTCCvdYThcpRifGmxbh?= MYGyN|MyPzR2Nh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. [1]

お薦めの試験操作(参考用のみ)

溶解度 (25°C)

体外 DMSO 30 mg/mL (57.74 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
8 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 519.56
化学式

C23H20F3N5O2S2

CAS No. 1195765-45-7
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01723202 Active, not recruiting Follicular Thyroid Cancer|Insular Thyroid Cancer|Papillary Thyroid Cancer|Recurrent Thyroid Cancer Manisha Shah|National Comprehensive Cancer Network|Ohio State University Comprehensive Cancer Center November 7, 2012 Phase 2
NCT02672358 Not yet recruiting Non-Small-Cell Lung Cancer Novartis Pharmaceuticals|Novartis October 2017 Phase 2
NCT02447939 Withdrawn Melanoma GlaxoSmithKline May 2017 Phase 1
NCT02967692 Not yet recruiting Melanoma Novartis Pharmaceuticals|Novartis February 2017 Phase 3
NCT02858921 Not yet recruiting Melanoma Melanoma Institute Australia|Merck Sharp & Dohme Corp.|Novartis February 2017 Phase 2
NCT03026517 Recruiting Melanoma Memorial Sloan Kettering Cancer Center|Massachusetts General Hospital|Weill Medical College of Cornell University January 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Raf信号経路図

Raf Inhibitors with Unique Features

相関Raf製品

Tags: Dabrafenib (GSK2118436)を買う | Dabrafenib (GSK2118436) ic50 | Dabrafenib (GSK2118436)供給者 | Dabrafenib (GSK2118436)を購入する | Dabrafenib (GSK2118436)費用 | Dabrafenib (GSK2118436)生産者 | オーダーDabrafenib (GSK2118436) | Dabrafenib (GSK2118436)化学構造 | Dabrafenib (GSK2118436)分子量 | Dabrafenib (GSK2118436)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID